Advertisement
Canada markets closed

  • S&P/TSX

    21,885.38
    +11.66 (+0.05%)
     

  • S&P 500

    5,048.42
    -23.21 (-0.46%)
     

  • DOW

    38,085.80
    -375.12 (-0.98%)
     

  • CAD/USD

    0.7323
    -0.0000 (-0.01%)
     

  • CRUDE OIL

    83.89
    +0.32 (+0.38%)
     

  • Bitcoin CAD

    87,394.06
    -728.09 (-0.83%)
     

  • CMC Crypto 200

    1,388.18
    +5.60 (+0.41%)
     

  • GOLD FUTURES

    2,338.90
    -3.60 (-0.15%)
     

  • RUSSELL 2000

    1,981.12
    -14.31 (-0.72%)
     

  • 10-Yr Bond

    4.7060
    +0.0540 (+1.16%)
     

  • NASDAQ futures

    17,752.75
    +185.25 (+1.05%)
     

  • VOLATILITY

    15.37
    -0.60 (-3.76%)
     

  • FTSE

    8,078.86
    +38.48 (+0.48%)
     

  • NIKKEI 225

    37,610.94
    -17.54 (-0.05%)
     

  • CAD/EUR

    0.6824
    +0.0003 (+0.04%)
     

Stocks in play: Cardiol Therapeutics Inc.

Baystreet.ca

Announced that the U.S. Food and Drug Administration (FDA) has provided clearance to proceed with the Company's Investigational New Drug (IND) application to commence a Phase II, multi-center, double-blind, randomized, placebo-controlled trial designed to study the safety and tolerability of CardiolRx™, as well as its impact on myocardial recovery in patients presenting with acute myocarditis. Cardiol Therapeutics Inc. shares T.CRDL are trading up $0.13 at $3.94.

Read: